Down-regulated expression of NPM1 in IMS-M2 cell line by (−)-epigallocatechin-3-gallate

Objective: To investigate the inhibited effect of epigallocatechin-3-gallate (EGCG) on the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. Methods: Cell proliferation assay was performed to test the effects of EGCG on cell growth of IMS-M2 cells harboring the NPM1 mutations. Western...

Full description

Bibliographic Details
Published in:Asian Pacific Journal of Tropical Biomedicine
Main Authors: Hoang Thanh Chi, Bui Thi Kim Ly, Hoang Anh Vu, Yuko Sato, Phu Chi Dung, Phan Thi Xinh
Format: Article in Journal/Newspaper
Language:English
Published: Wolters Kluwer Medknow Publications 2014
Subjects:
NPM1
EGCG
IMS-M2
Apoptosis
Arctic medicine. Tropical medicine
RC955-962
Biology (General)
QH301-705.5
Arctic
Online Access:https://doi.org/10.12980/APJTB.4.2014APJTB-2014-0177
https://doaj.org/article/44b3460fa70f4c5886aebf97d6dfd092
Description
Summary:Objective: To investigate the inhibited effect of epigallocatechin-3-gallate (EGCG) on the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. Methods: Cell proliferation assay was performed to test the effects of EGCG on cell growth of IMS-M2 cells harboring the NPM1 mutations. Western blot analysis were performed to test the protein expression of NPM1, AKT, those associated with apoptosis. Results: EGCG can down-regulate the expression of NPM1 in IMS-M2 cells harboring the NPM1 mutations. Moreover, EGCG also suppressed the cell proliferation and induced apoptosis in IMS-M2 cells. Conclusions: The results suggested that EGCG could be considered as a reagent for treatment of AML patients with NPM1 mutations.

Similar Items